Original article published by MedCity News on January 15, 2026
In this MedCity News article, Naomi Fried, founder and CEO of PharmStars, shares her predictions for the future of digital innovation in the pharmaceutical industry. She discusses how 2026 will mark the transition from AI hype to the widespread adoption of practical AI and digital health solutions, highlighting trends toward greater operational efficiency, the rise of agentic AI in drug development, and the increasing importance of digital biomarkers and real-world data in accelerating innovation.
You can read the article here.
Naomi Fried, PhD
Naomi Fried, PhD, is the founder and CEO of PharmStars. She is also a founder and Managing Partner of the PharmStars Ventures Fund, which invests in the PharmStars accelerator’s graduates. Previously, she was a Partner at Ambit Health Ventures which invested in early-stage digital health device and therapeutic startups. Prior to that, Naomi was the CEO of the consulting firm Health Innovation Strategies, VP of Innovation and External Partnerships at Biogen, the first Chief Innovation Officer at Boston Children’s Hospital, and the first VP of Innovation and Advanced Technology at Kaiser Permanente. She advises and is on the boards of digital health startups.
View All Posts
